Proceeds

Axogen has priced an upsized public offering of common stock, aiming to raise approximately $124 million in gross proceeds. The company intends to use these funds to pay off its term loan facility, bolster working capital, and support future growth initiatives. This move follows recent strong revenue reports and FDA approval for its AVANCE product, positioning Axogen for continued expansion in the peripheral nerve repair market.

YY Group (YYGH) closed a registered direct offering, raising $4.0 million. The offering included 9,523,812 Class A shares at $0.42 each, plus warrants for up to 14,285,718 additional shares at $0.50, exercisable within 3.5 years. FT Global Capital was the placement agent. Proceeds will fund working capital and general corporate activities. The offering was made under a shelf registration statement.